Carrick Therapeutics

Carrick Therapeutics needs a specialized CRO with proven experience in phase 3 multinational breast cancer trials. In this visual case study, we rescued a struggling trial which was phase 2 moving into phase 3. Precision had the right relationships with KOLs and investigator sites having the specific expertise needed for this trial.

Feasibility acumen was identified by Carrick as a critical selection criterion. This recent narrative case study is a deep dive into Precision’s process for large multinational phase 3 solid tumor studies. The study spanned 230 sites across 17 countries with a complex patient population, with activation of the first 77 sites across the US and Europe within four months.

As an oncology specialist CRO, we understand how evolving regulatory requirements can impact Carrick’s trial planning, design, and execution. In fact, nobody understands this more than our Chief Medical Officer, Harpreet Singh, MD. As a former FDA Director, Division of Oncology 2, she brings a unique perspective to the table. See her recent white paper on Multi Regional Clinical Trials, also available in one-page summary format.

The MRCTs white paper by Dr. Harpreet Singh is a detailed deep dive into the topic. As a companion piece, we’ve made this single-page top takeaways document to highlight six specific insights from the white paper, each paired with actions a sponsor can take during trial design. 

Because of the critical nature of investigator sites to Carrick’s success, we want to familiarize you with the specifics of our Precision Site Network. While we maintain strong relationships with many investigators across the globe, we have invested in relationships with a highly curated group of high-performing sites that tend to outperform others. Our focus is on performance and collaboration, not quantity of sites.

Learn more

To support a diverse mix of sites around APAC, Precision has invested in offices, staff, and industry relationships across the region. We have recently opened our fourth office in the Greater China market, and recently posted this blog about our strategy which includes two mainland China offices, plus one in Hong Kong and one in Taiwan enables us to adhere to the regional regulatory structures while maintaining close relationships with investigator sites.